GlobeNewswire: Sensorion Contains the last 10 of 29 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T09:34:19ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/02/13/1724347/0/en/Sensorion-to-Present-New-SENS-401-Data-at-ARO-2019-MidWinter-Meeting-Feb-9-13-2019.html?f=22&fvtc=4&fvtv=39768Sensorion to Present New SENS-401 Data at ARO 2019 MidWinter Meeting, Feb. 9-13, 20192019-02-13T06:30:00Z<![CDATA[Two poster presentations to show growing evidence base for SENS-401 in inner ear disease Two poster presentations to show growing evidence base for SENS-401 in inner ear disease]]>https://www.globenewswire.com/news-release/2018/12/21/1677422/0/en/Sensorion-Announces-Publication-of-SENS-401-Data-in-Otology-Neurology-Journal.html?f=22&fvtc=4&fvtv=39768Sensorion Announces Publication of SENS-401 Data in Otology & Neurology Journal2018-12-21T06:30:00Z<![CDATA[Improvement of hearing recovery above threshold for clinical relevance when SENS-401 was administered daily for 28 days delayed as much as 96 hrs after acoustic trauma in a preclinical model Improvement of hearing recovery above threshold for clinical relevance when SENS-401 was administered daily for 28 days delayed as much as 96 hrs after acoustic trauma in a preclinical model]]>https://www.globenewswire.com/news-release/2018/12/14/1667094/0/en/Sensorion-Announces-Positive-Topline-Results-From-Seliforant-Phase-2a-Study.html?f=22&fvtc=4&fvtv=39768Sensorion Announces Positive Topline Results From Seliforant Phase 2a Study2018-12-14T06:30:00Z<![CDATA[Results confirmed Seliforant does not affect vigilance, cognitive performance during a motion stimulus Results confirmed Seliforant does not affect vigilance, cognitive performance during a motion stimulus]]>https://www.globenewswire.com/news-release/2018/12/07/1663559/0/en/Sensorion-Announces-a-Publication-in-Hearing-Research-on-Kinetics-of-Prestin-Blood-Levels-After-Noise-Trauma-Induced-Hearing-Loss.html?f=22&fvtc=4&fvtv=39768Sensorion Announces a Publication in Hearing Research on Kinetics of Prestin Blood Levels After Noise Trauma-Induced Hearing Loss2018-12-07T06:35:00Z<![CDATA[Circulating levels of prestin may act as surrogate biomarker for hearing loss involving OHC loss Circulating levels of prestin may act as surrogate biomarker for hearing loss involving OHC loss]]>https://www.globenewswire.com/news-release/2018/11/27/1657095/0/en/Sensorion-Announces-Completion-of-Patient-Enrollment-and-Dosing-in-Seliforant-Phase-2a-Study.html?f=22&fvtc=4&fvtv=39768Sensorion Announces Completion of Patient Enrollment and Dosing in Seliforant Phase 2a Study2018-11-27T06:00:00Z<![CDATA[First results are expected by the end of the year First results are expected by the end of the year]]>https://www.globenewswire.com/news-release/2018/11/23/1655864/0/en/Sensorion-Enters-Into-Exclusive-Negotiations-with-Pasteur-Institute-for-Hearing-Loss-Gene-Therapy-Programs.html?f=22&fvtc=4&fvtv=39768Sensorion Enters Into Exclusive Negotiations with Pasteur Institute for Hearing Loss Gene Therapy Programs2018-11-23T06:00:00Z<![CDATA[MONTPELLIER, France, Nov. 23, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN / PEA-PME eligible) announced today that it has entered into a letter of intent with Pasteur Institute (Paris, France) to exclusively negotiate a framework agreement to obtain the exclusive licenses to develop and commercialize gene therapy product candidates for restoration, treatment and prevention of hearing loss disorders.]]>https://www.globenewswire.com/news-release/2018/11/07/1646637/0/en/Sensorion-Announces-Presentation-of-SENS-401-Poster-at-Society-for-Neuroscience-2018-Annual-Meeting.html?f=22&fvtc=4&fvtv=39768Sensorion Announces Presentation of SENS-401 Poster at Society for Neuroscience 2018 Annual Meeting2018-11-07T07:00:00Z<![CDATA[Preclinical data suggest efficacy of SENS-401 is not affected by concomitant administration of a corticosteroid]]>https://www.globenewswire.com/news-release/2018/10/18/1623682/0/en/Sensorion-Reports-Pipeline-Update-and-First-Half-Year-2018-Results-Re-design-of-SENS-111-Study.html?f=22&fvtc=4&fvtv=39768Sensorion Reports Pipeline Update and First-Half-Year 2018 Results; Re-design of SENS-111 Study2018-10-18T17:43:29Z<![CDATA[MONTPELLIER, France, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN / PEA-PME eligible), a biotech company pioneering novel treatments of inner ear diseases, today announces its results for the first half of the year ending June 30, 2018, as well as its recent developments.]]>https://www.globenewswire.com/news-release/2018/09/26/1576152/0/en/Sensorion-Announces-Publication-of-Seliforant-Phase-1-Study-Data-in-the-British-Journal-of-Clinical-Pharmacology.html?f=22&fvtc=4&fvtv=39768Sensorion Announces Publication of Seliforant Phase 1 Study Data in the British Journal of Clinical Pharmacology2018-09-26T05:30:00Z<![CDATA[Study of safety, tolerability, pharmacokinetics, and pharmacokinetic-pharmacodynamic modelling of Seliforant]]>https://www.globenewswire.com/news-release/2018/09/10/1568256/0/en/Sensorion-to-Partner-with-Vestibular-Disorders-Association-VeDA-in-Sponsorship-of-Balance-Awareness-Week-2018-for-Vestibular-Disorders.html?f=22&fvtc=4&fvtv=39768Sensorion to Partner with Vestibular Disorders Association (VeDA) in Sponsorship of Balance Awareness Week 2018 for Vestibular Disorders2018-09-10T05:30:00Z<![CDATA[MONTPELLIER, France, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announces that it has joined with the Vestibular Disorders Association (VeDA) to help educate the public and raise awareness of balance and vestibular disorders on the occasion of the Balance Awareness week, which takes place this year for September 16 to 22.]]>